Telomir Pharmaceuticals (TELO) Competitors $2.51 -0.04 (-1.57%) Closing price 04:00 PM EasternExtended Trading$2.50 0.00 (-0.20%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. ATAI, MBX, PVLA, GLUE, RNAC, AURA, PHAT, CYRX, ITOS, and SEPNShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Atai Life Sciences (ATAI), MBX Biosciences (MBX), Palvella Therapeutics (PVLA), Monte Rosa Therapeutics (GLUE), Cartesian Therapeutics (RNAC), Aura Biosciences (AURA), Phathom Pharmaceuticals (PHAT), Cryoport (CYRX), iTeos Therapeutics (ITOS), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Atai Life Sciences MBX Biosciences Palvella Therapeutics Monte Rosa Therapeutics Cartesian Therapeutics Aura Biosciences Phathom Pharmaceuticals Cryoport iTeos Therapeutics Septerna Atai Life Sciences (NASDAQ:ATAI) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Which has better earnings and valuation, ATAI or TELO? Telomir Pharmaceuticals has lower revenue, but higher earnings than Atai Life Sciences. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtai Life Sciences$308K945.78-$40.22M-$0.93-1.57Telomir PharmaceuticalsN/AN/A-$16.53M-$0.58-4.27 Is ATAI or TELO more profitable? Atai Life Sciences' return on equity of -65.75% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atai Life SciencesN/A -65.75% -52.71% Telomir Pharmaceuticals N/A -1,170.58%-832.67% Do insiders & institutionals believe in ATAI or TELO? 28.4% of Atai Life Sciences shares are owned by institutional investors. 31.2% of Atai Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate ATAI or TELO? Atai Life Sciences presently has a consensus price target of $10.50, indicating a potential upside of 620.16%. Telomir Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 505.08%. Given Atai Life Sciences' higher probable upside, analysts clearly believe Atai Life Sciences is more favorable than Telomir Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media favor ATAI or TELO? In the previous week, Atai Life Sciences and Atai Life Sciences both had 1 articles in the media. Atai Life Sciences' average media sentiment score of 1.89 beat Telomir Pharmaceuticals' score of 1.18 indicating that Atai Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Atai Life Sciences Very Positive Telomir Pharmaceuticals Positive Which has more volatility and risk, ATAI or TELO? Atai Life Sciences has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Does the MarketBeat Community believe in ATAI or TELO? Atai Life Sciences received 332 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Telomir Pharmaceuticals an outperform vote while only 66.53% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformAtai Life SciencesOutperform Votes33466.53% Underperform Votes16833.47% Telomir PharmaceuticalsOutperform Votes2100.00% Underperform VotesNo Votes SummaryAtai Life Sciences beats Telomir Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.54M$6.72B$5.49B$7.94BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-4.267.3722.5818.55Price / SalesN/A242.94397.25103.00Price / CashN/A65.8538.1834.62Price / Book123.956.486.704.26Net Income-$16.53M$143.68M$3.23B$248.39M7 Day Performance-3.16%1.79%1.26%1.27%1 Month Performance-9.53%6.68%3.75%3.85%1 Year Performance-63.65%-2.73%15.78%5.23% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals2.5082 of 5 stars$2.51-1.6%$15.00+497.6%-61.5%$74.71MN/A-4.331News CoverageATAIAtai Life Sciences2.6868 of 5 stars$1.44+1.5%$10.50+628.7%-24.2%$292.68M$308,000.00-1.8180MBXMBX Biosciences2.5978 of 5 stars$8.58+12.2%$37.50+337.3%N/A$288.88MN/A0.0036PVLAPalvella Therapeutics3.4144 of 5 stars$26.14+2.7%$44.43+70.0%N/A$288.04M$42.81M-2.16N/AAnalyst ForecastPositive NewsGLUEMonte Rosa Therapeutics1.9755 of 5 stars$4.67+4.7%$15.50+231.9%-7.7%$287.25M$75.62M-2.5590Upcoming EarningsShort Interest ↑News CoveragePositive NewsRNACCartesian Therapeutics1.9639 of 5 stars$11.02+6.6%$42.14+282.4%-45.6%$285.50M$38.91M-0.2164Upcoming EarningsPositive NewsAURAAura Biosciences2.334 of 5 stars$5.68+2.0%$22.75+300.2%-21.2%$283.77MN/A-3.2750Upcoming EarningsShort Interest ↑News CoverageGap DownPHATPhathom Pharmaceuticals4.0455 of 5 stars$3.98+2.1%$21.83+448.6%-52.5%$278.20M$55.25M-0.70110News CoveragePositive NewsGap DownCYRXCryoport2.3869 of 5 stars$5.520.0%$11.67+111.4%-65.5%$274.66M$228.39M-1.631,020Upcoming EarningsITOSiTeos Therapeutics2.0969 of 5 stars$7.11+7.3%$25.75+262.4%-32.5%$268.50M$35M-2.2390Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsSEPNSepterna2.2526 of 5 stars$5.97+1.8%$33.00+452.5%N/A$265.10M$1.08M0.00N/ANews CoveragePositive News Related Companies and Tools Related Companies Atai Life Sciences Alternatives MBX Biosciences Alternatives Palvella Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Cartesian Therapeutics Alternatives Aura Biosciences Alternatives Phathom Pharmaceuticals Alternatives Cryoport Alternatives iTeos Therapeutics Alternatives Septerna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TELO Stock Free TELO Stock Alerts